| A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM (NCT02766699) | Engeneic Pty Limited | 2016-10-25 |
| Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma (NCT02669173) | Case Comprehensive Cancer Center | 2016-10-11 |
| Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (NCT02798406) | DNAtrix, Inc. | 2016-10-06 |
| Enhancing Optune Therapy With Targeted Craniectomy (NCT02893137) | Aarhus University Hospital | 2016-10-01 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889) | AbbVie | 2016-09-23 |
| Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma (NCT02768389) | Case Comprehensive Cancer Center | 2016-09-06 |
| Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma (NCT02876003) | GenSpera, Inc. | 2016-09-01 |
| Discerning Pseudoprogression vs True Tumor Growth in GBMs (NCT02905643) | Ascension Health | 2016-09-01 |
| Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer (NCT02903069) | Celgene | 2016-08-17 |
| Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (NCT02465268) | University of Florida | 2016-08-09 |
| A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging (NCT04691960) | Weill Medical College of Cornell University | 2016-08-01 |
| Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI (NCT02843230) | Massachusetts General Hospital | 2016-08-01 |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (NCT02761070) | Kyorin University | 2016-07-11 |
| Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma (NCT02919332) | Jonsson Comprehensive Cancer Center | 2016-06-08 |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma (NCT02861898) | Northwell Health | 2016-06-01 |
| Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma (NCT02844439) | Kadmon Corporation, LLC | 2016-06-01 |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (NCT02661282) | M.D. Anderson Cancer Center | 2016-06-01 |
| Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma (NCT02648633) | University of Virginia | 2016-05-24 |
| Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma (NCT02769806) | University of Wisconsin, Madison | 2016-05-23 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| Ceritinib Rare Indications Study in ALK+ Tumors (NCT02465528) | Novartis Pharmaceuticals | 2016-05-06 |
| HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors (NCT02457845) | Gregory K. Friedman, MD | 2016-05-01 |
| VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma (NCT02718443) | Vaximm GmbH | 2016-05-01 |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors (NCT02644291) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-05-01 |
| Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma (NCT02728349) | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 2016-04-12 |
| A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas (NCT02750891) | Sumitomo Pharma Co., Ltd. | 2016-04-01 |
| Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma (NCT02630030) | Emory University | 2016-03-24 |
| Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery (NCT02590497) | Ohio State University Comprehensive Cancer Center | 2016-03-20 |
| Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas. (NCT03115138) | Centre Hospitalier Universitaire, Amiens | 2016-03-09 |
| Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma (NCT02345824) | University of Virginia | 2016-03-01 |
| Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma (NCT02833701) | University of Nebraska | 2016-03-01 |
| Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) (NCT02709616) | Guangdong 999 Brain Hospital | 2016-03-01 |
| Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis (NCT02605746) | St. Joseph's Hospital and Medical Center, Phoenix | 2016-02-17 |
| Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma (NCT02715297) | Technical University of Munich | 2016-02-01 |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. (NCT04610229) | Azienda USL Reggio Emilia - IRCCS | 2016-02-01 |
| Oral ONC201 in Adult Recurrent Glioblastoma (NCT02525692) | Jazz Pharmaceuticals | 2016-01-01 |
| Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas (NCT02585219) | University Medical Center Groningen | 2016-01-01 |
| Glioblastoma Platelet Activation Study (NCT02887417) | University Medicine Greifswald | 2016-01-01 |
| Nivolumab With DC Vaccines for Recurrent Brain Tumors (NCT02529072) | Gary Archer Ph.D. | 2016-01-01 |
| Radiomics for Prediction of Survival in GBM (NCT02666066) | Maastricht Radiation Oncology | 2016-01-01 |
| Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (NCT01931098) | National Cancer Institute (NCI) | 2015-12-10 |
| POSitron Emission Imaging Using 18F-FDOPA in Neurooncology (NCT02631655) | Centre Antoine Lacassagne | 2015-12-01 |
| Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid (NCT02617745) | Centre Henri Becquerel | 2015-11-30 |
| A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme (NCT05600491) | Sun Yat-sen University | 2015-11-08 |
| IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma (NCT02910804) | Beijing Tiantan Hospital | 2015-11-01 |
| More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery (NCT01445691) | Constantinos Hadjipanayis | 2015-11-01 |
| DC Migration Study for Newly-Diagnosed GBM (NCT02366728) | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 2015-10-12 |
| FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma (NCT02902757) | Jonsson Comprehensive Cancer Center | 2015-08-25 |
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors (NCT02372409) | Washington University School of Medicine | 2015-08-14 |
| A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) (NCT02511405) | Vascular Biogenics Ltd. operating as VBL Therapeutics | 2015-08-01 |
| Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma (NCT02478164) | Dana-Farber Cancer Institute | 2015-07-13 |
| Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma (NCT03770468) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-07-05 |
| Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma (NCT02698280) | Huashan Hospital | 2015-07-01 |
| A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma (NCT02490930) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-07-01 |
| Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas (NCT02379572) | University Hospital Tuebingen | 2015-06-01 |
| Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model (NCT02904525) | Andreas Hottinger | 2015-06-01 |
| SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (NCT02455557) | Roswell Park Cancer Institute | 2015-05-04 |
| A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy (NCT02431572) | Massachusetts General Hospital | 2015-05-01 |
| Surgery for Recurrent Glioblastoma (NCT02394626) | Insel Gruppe AG, University Hospital Bern | 2015-05-01 |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab (NCT02330562) | Celgene | 2015-04-15 |
| 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme (NCT02410577) | Memorial Sloan Kettering Cancer Center | 2015-04-01 |
| Using Genomic Analysis to Guide Individual Treatment in Glioblastoma (NCT02725684) | Rockefeller University | 2015-03-12 |
| qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. (NCT02466828) | Sunnybrook Health Sciences Centre | 2015-03-01 |
| Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma (NCT02394665) | University of Miami | 2015-03-01 |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (NCT02343406) | AbbVie | 2015-02-17 |
| Pembrolizumab +/- Bevacizumab for Recurrent GBM (NCT02337491) | Dana-Farber Cancer Institute | 2015-02-09 |
| Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers (NCT02375841) | Memorial Sloan Kettering Cancer Center | 2015-02-01 |
| Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma (NCT02254954) | Actelion | 2015-01-08 |
| A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (NCT02573324) | AbbVie | 2015-01-04 |
| TMS Electrochemotherapy for Glioblastoma Multiforme (NCT02283944) | University of Aarhus | 2015-01-01 |
| MRI Detection of Microbleeds in Glioma Patients (NCT02899663) | Fondation Ophtalmologique Adolphe de Rothschild | 2015-01-01 |
| Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients (NCT02520635) | Beijing Tiantan Hospital | 2015-01-01 |
| A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse (NCT02330991) | Beijing Sanbo Brain Hospital | 2015-01-01 |
| Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT02152982) | National Cancer Institute (NCI) | 2014-12-15 |
| Spatial Analysis and Validation of Glioblastoma on 7 T MRI (NCT02062372) | Maastricht Radiation Oncology | 2014-12-10 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (NCT02238496) | Andrew B Lassman, MD | 2014-12-08 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (NCT02327078) | Incyte Corporation | 2014-11-26 |
| Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme (NCT02575027) | Jonsson Comprehensive Cancer Center | 2014-11-12 |
| Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (NCT02287428) | Dana-Farber Cancer Institute | 2014-11-01 |
| Preoperative Chemoradiation for Glioblastoma (NCT02092038) | Tampa General Hospital | 2014-11-01 |
| Image-derived Prediction of Response to Chemo-radiation in Glioblastoma (NCT02329795) | Rigshospitalet, Denmark | 2014-10-01 |
| GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (NCT02149225) | Immatics Biotechnologies GmbH | 2014-10-01 |
| A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 (NCT01985087) | University of Louisville | 2014-09-01 |
| 89Zr-RO5323441 PET Imaging in Glioblastoma (NCT01622764) | University Medical Center Groningen | 2014-09-01 |
| Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. (NCT02209948) | Grupo Español de Investigación en Neurooncología | 2014-08-22 |
| Prevention of Thrombocytopenia in Glioblastoma Patients (NCT02227576) | University Hospital, Lille | 2014-07-10 |
| Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (NCT02133183) | National Cancer Institute (NCI) | 2014-07-02 |
| Tryptophan Metabolism in Human Brain Tumors-Novocure (NCT02367482) | Wayne State University | 2014-07-01 |
| A Phase 0 Study of AZD1775 in Recurrent GBM Patients (NCT02207010) | St. Joseph's Hospital and Medical Center, Phoenix | 2014-07-01 |
| Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas (NCT02473484) | University Hospital, Lille | 2014-06-24 |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma (NCT02168270) | University of Nebraska | 2014-06-16 |
| Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma (NCT02176720) | The Methodist Hospital Research Institute | 2014-05-01 |
| Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner (NCT02129335) | University Hospital, Basel, Switzerland | 2014-04-01 |
| Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas (NCT01986348) | Karyopharm Therapeutics Inc | 2014-03-03 |
| ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (NCT01903330) | Epitopoietic Research Corporation | 2014-03-01 |
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (NCT02014844) | ImmunityBio, Inc. | 2014-03-01 |
| Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics (NCT02047058) | Nanfang Hospital, Southern Medical University | 2014-03-01 |
| Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma (NCT01898273) | Cellectar Biosciences, Inc. | 2014-02-01 |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma (NCT02010606) | Cedars-Sinai Medical Center | 2014-01-08 |
| Derivation of Tumor Specific Hybridomas (NCT01702792) | Dartmouth-Hitchcock Medical Center | 2014-01-01 |